Complete response to erlotinib treatment in brain metastases from recurrent NSCLC
Open Access
- 21 October 2005
- Vol. 61 (1), 91
- https://doi.org/10.1136/thx.2005.052233
Abstract
In December 2004 she developed progressively worsening pulmonary and neurological symptoms including dizziness. An MRI scan showed cerebral metastases with lesions in the left and right parietal lobes (fig 1A). She was commenced on third line therapy with erlotinib (Roche, 150 mg daily). Within a week of starting treatment her neurological symptoms resolved and her breathlessness improved. An MRI scan taken 6 weeks after starting erlotinib showed a complete response of brain metastases (fig 1B). Six months after starting treatment she remains clinically well on erlotinib without chest related or neurological symptoms except for a grade 1 skin rash.Keywords
This publication has 5 references indexed in Scilit:
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future DirectionsJournal of Clinical Oncology, 2005
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005
- Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)Lung Cancer, 2003